ReviewBiomedical reports2026
Cellular signaling crosstalk between osteoporosis and diabetes: Common mechanisms and therapeutic targets (Review).
Review in Biomedical reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis and diabetes typically occur together. The present review aimed to summarize the molecular mechanisms and intracellular signaling pathways that connect osteoporosis and diabetes. In diabetic conditions, persistent hyperglycemia triggers excessive oxidative stress, sustains low-grade inflammation and perturbs insulin signaling pathways. In turn, bone metabolic abnormalities affect glucose regulation through the bone-pancreas axis and osteoimmune signaling pathways, highlighting a bidirectional relationship between skeletal and metabolic health. Several antidiabetic agents (metformin, glucagon-like peptide-1 receptor agonists) protect against bone loss, while certain anti-osteoporotic drugs (bisphosphonates, denosumab) exert favorable effects on glucose metabolism and diabetic complications. These dual benefits suggest overlapping molecular pathways and shared therapeutic targets. The present review aimed to summarize the inflammation-insulin signaling axis, RANKL/OPG system, Wnt/β-catenin pathway, AGE/RAGE signaling and bone-derived endocrine factors as key mediators of interorgan communication. It also underscores the importance of systems biology and integrated cross-tissue analyses in uncovering the mechanisms underlying diabetes-associated bone disorder. Future research defining the molecular basis of intercellular and interorgan crosstalk may lead to precise, mechanism-driven strategies for the integrated treatment of diabetes and osteoporosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.